Biogen sells a number of medications for multiple sclerosis, such as Vumerity, Tecfidera, Tysabri, and Plegridy. Biogen’s more recent offerings are Qalsody (ALS, Ionis), Zurzuvae (postpartum ...

Our analysis of options history for Biogen BIIB revealed 12 unusual trades. Delving into the details, we found 25% of traders ...

It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of ...

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of ...

1 Pegylated IFN β-1a (PLEGRIDY®, Biogen) was US Food and Drug Administration (FDA)– and European Medicines Agency (EMA)–approved in 2014. Establishing new more holistic methods to evaluate ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...

Biogen Inc. (NASDAQ:BIIB ... and to a lesser extent, Plegridy - have lost their patent protection, and are experiencing revenue declines. The MS division's revenues fell from >$8.5bn in 2019 ...